Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Mycoses ; 65(4): 411-418, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-35138675

RESUMO

BACKGROUND: The diagnosis of invasive pulmonary aspergillosis (IPA) in intensive care unit (ICU) patients is challenging, and the role of Aspergillus-PCR in bronchoalveolar lavage (BAL) is unknown. OBJECTIVES: This study evaluated diagnostic accuracy of Aspergillus-PCR in BAL in IPA in three different cohorts: ICU-admitted patients with COVID-19, ICU-admitted patients without COVID-19 and immunocompromised patients. METHODS: All stored available BAL samples collected from three patient groups were tested with Aspergillus-PCR (AsperGenius® ). IPA was diagnosed according to appropriate criteria for each patient group. RESULTS: We included 111 BAL samples from 101 patients: 52 (51%) patients admitted to ICU for COVID-19, 24 (24%) admitted to ICU for other reasons and 25 (25%) immunocompromised. There were 31 cases of IPA (28%). Aspergillus-PCR sensitivity was 64% (95% CI 47-79) and specificity 99% (95% CI 93-100). Aspergillus-PCR sensitivity was 40% (95%CI 19-64) in ICU COVID-19, 67% (95% CI 21-93) in non-COVID-19 ICU patients and 92% (95%CI 67-98) in the immunocompromised. The concordance between positive BAL-GM and BAL-PCR in patients with and without IPA was significantly lower in ICU patients (32%; 43% in COVID-19, 18% in non-COVID-19) than in the immunocompromised (92%), p < .001. CONCLUSIONS: Aspergillus-PCR in BAL improves the diagnostic accuracy of BAL-GM in ICU patients.


Assuntos
COVID-19 , Aspergilose Pulmonar Invasiva , Aspergillus/genética , Lavagem Broncoalveolar , Líquido da Lavagem Broncoalveolar , COVID-19/diagnóstico , Estado Terminal , Galactose , Humanos , Aspergilose Pulmonar Invasiva/diagnóstico , Mananas/análise , Reação em Cadeia da Polimerase , Sensibilidade e Especificidade
2.
Biol Blood Marrow Transplant ; 26(7): 1355-1362, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32200124

RESUMO

Chronic hepatitis E virus (HEV) infection in hematopoietic stem cell transplantation (HSCT) recipients is an emerging threat. The aim of this study was to provide data on the HEV burden in an Italian cohort of HSCT recipients and analyze risk factors for HEV seropositivity. This retrospective study reports data from 596 HSCT recipients compiled between 2010 and 2019. It included patients who underwent transplantation between 2010 and 2015 for whom pretransplantation (n = 419) and post-transplantation (n = 161) serum samples were available and tested retrospectively, as well as patients in whom prospective HEV testing was performed during the standard care: pre-HSCT IgG screening in 144, pre-HSCT HEV-RNA screening in addition to IgG screening in 60, and HEV-RNA testing in case of clinical suspicion of HEV infection in 59 (26 of whom were also included in the IgG screening cohorts). The rate of pre-HSCT HEV-IgG positivity was 6.0% (34 of 563). Older age was an independent risk factor for seropositivity (P = .039). None of the 34 HEV-IgG-positive patients had detectable HEV-RNA. One case of transient HEV-RNA positivity pre-HSCT was identified through screening. Two patients were diagnosed with chronic HEV hepatitis, and 1 patient was successfully treated with ribavirin. The burden of HEV infection in HSCT recipients in Italy is limited, and pre-HSCT screening appears to be of no benefit. Timely diagnosis of HEV infection with HEV-RNA is mandatory in cases of clinical suspicion.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Vírus da Hepatite E , Hepatite E , Idoso , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Hepatite E/diagnóstico , Hepatite E/epidemiologia , Hepatite E/etiologia , Vírus da Hepatite E/genética , Humanos , Itália/epidemiologia , Estudos Prospectivos , RNA Viral , Estudos Retrospectivos , Estudos Soroepidemiológicos
3.
Eur J Clin Microbiol Infect Dis ; 38(2): 413-417, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30506332

RESUMO

Desirability of outcome ranking (DOOR) has been developed for assessing desirability of outcome in interventional studies. However, its possible use in observational studies of the diagnosis and early treatment of infectious diseases has not been explored so far, and it might introduce interesting features in specific scenarios. This was a post hoc analysis of a prospective observational study in intensive care unit patients with sepsis and at risk of candidemia. The probabilities that a randomly selected patient would have a more, less, and equally cost-effective early therapeutic choice following a BDG-based diagnostic strategy rather than the empirical administration of antifungals to all patients were calculated using DOOR methods. The probability of a more cost-effective therapeutic choice following the BDG-based rather than the empirical strategy was 67.81% (95% CI 67.32-68.30), whereas the probabilities of a less and equally cost-effective early therapeutic choice were 19.68% (95% CI 19.27-20.10) and 12.50% (95% CI 12.16-12.85), respectively. The application of DOOR methods to observational studies focused on diagnosis and early treatment is a novel field that could merit further investigation.


Assuntos
Antifúngicos/uso terapêutico , Antígenos de Fungos/sangue , Candidemia/diagnóstico , Candidemia/tratamento farmacológico , Análise Custo-Benefício , beta-Glucanas/sangue , Antifúngicos/economia , Gerenciamento Clínico , Fungos/imunologia , Humanos , Unidades de Terapia Intensiva , Estudos Prospectivos , Sepse/etiologia , Resultado do Tratamento
4.
Med Mycol ; 57(8): 987-996, 2019 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-30753590

RESUMO

Diagnosis of invasive aspergillosis (IA) is challenging, particularly in high-risk patients with lung lesions other than typical according to 2008-EORTC/MSG criteria. Even if microbiology is positive, they still remain unclassified according to 2008-EORTC/MSG. Quantitative polymerase chain reaction (qPCR) provides new mycological documentation of IA. This retrospective study assessed Aspergillus fumigatus real time qPCR (MycoGENIE®) in BAL to diagnose IA and identify azole-resistant strains. Clinical, radiological, and microbiological data from 114 hematology patients (69% HSCT recipients; 29% on mould active agents) from years 2012-2017 were collected; and 123 BAL samples were tested with qPCR (cutoff: Ct < 40) and galactomannan (GM, Platelia®, cutoff: 0.5 ODI). Patients were classified as proven/probable, possible, and no-IA. "Atypical-IA" referred to patients with lesions other than typical according to 2008-EORTC/MSG and positive mycology. Proven IA was diagnosed in two cases (1.6%), probable in 28 (22.8%), possible in 27 (22%), atypical in 14 (11.4%). qPCR was positive in 39 samples (31.7%). Sensitivity and specificity of qPCR for proven/probable IA (vs no-IA; atypical-IA excluded) were 40% (95% confidence interval [CI]: 23-59) and 69% (95%CI: 55-81), respectively. Sensitivity of qPCR was higher when combined with GM (83%, 95%CI: 65-94) and in those receiving mould-active agents at BAL (61%, 95%CI: 32-86). One sample had TR34/L98H mutation. In conclusion, in high-risk hematology patients with various lung lesions, A. fumigatus qPCR in BAL contributes to diagnosing IA, particularly if combined with GM and in patients receiving mould-active agents might allow detecting azole-resistant mutations in culture negative samples.


Assuntos
Aspergillus fumigatus/isolamento & purificação , Análise Química do Sangue/métodos , Líquido da Lavagem Broncoalveolar/microbiologia , Aspergilose Pulmonar Invasiva/diagnóstico , Mananas/sangue , Técnicas de Diagnóstico Molecular/métodos , Reação em Cadeia da Polimerase em Tempo Real/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Galactose/análogos & derivados , Neoplasias Hematológicas/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Sensibilidade e Especificidade , Fatores de Tempo , Adulto Jovem
5.
Mycoses ; 61(9): 650-655, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-29693758

RESUMO

We report our experience with the use of (1,3)-ß-d-glucan (BDG) screening for the diagnosis of invasive aspergillosis (IA) in neutropenic patients with haematological malignancies. The performance of BDG screening was assessed retrospectively in per patient and per sample analyses. Overall, 20 among 167 patients developed IA (12%). In the per patient analysis, BDG showed 60% sensitivity and 78% specificity when the criterion for positivity was the presence of at least one BDG value ≥80 pg/mL. For 2 consecutive positive results, sensitivity decreased to 40%, while specificity increased to 93% and was similar to that of a positive galactomannan (GM; 90%). The highest specificity (97%) was observed for combined positivity of at least one BDG and at least one GM. In the per sample analysis, the specificity of BDG was 100% in the best scenario, 96% in the median scenario and 89% in the worst scenario. BDG became positive before GM in 33% of IA patients with both markers positive (n = 12). Despite good specificity for 2 consecutive positive results, the BDG test offered unsatisfactory performance for the diagnosis of IA due to low sensitivity. The combination of BDG and GM showed the potential for increasing specificity.


Assuntos
Biomarcadores/sangue , Testes Diagnósticos de Rotina/métodos , Neoplasias Hematológicas/complicações , Aspergilose Pulmonar Invasiva/diagnóstico , Programas de Rastreamento/métodos , Neutropenia/complicações , beta-Glucanas/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Proteoglicanas , Estudos Retrospectivos , Sensibilidade e Especificidade , Soro/química , Adulto Jovem
6.
Crit Care ; 21(1): 176, 2017 Jul 10.
Artigo em Inglês | MEDLINE | ID: mdl-28693606

RESUMO

BACKGROUND: This study aimed to assess the combined performance of serum (1,3)-ß-D-glucan (BDG) and procalcitonin (PCT) for the differential diagnosis between candidaemia and bacteraemia in three intensive care units (ICUs) in two large teaching hospitals in Italy. METHODS: From June 2014 to December 2015, all adult patients admitted to the ICU who had a culture-proven candidaemia or bacteraemia, as well as BDG and PCT measured closely to the time of the index culture, were included in the study. The diagnostic performance of BDG and PCT, used either separately or in combination, was assessed by calculating the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and positive and negative likelihood ratios (LR+ and LR-). Changes from pre-test probabilities to post-test probabilities of candidaemia and bacteraemia were inferred from Fagan's nomograms. RESULTS: One hundred and sixty-six patients were included, 73 with candidaemia (44%) and 93 with bacteraemia (56%). When both markers indicated candidaemia (BDG ≥80 pg/ml and PCT <2 ng/ml) they showed higher PPV (96%) compared to 79% and 66% for BDG or PCT alone, respectively. When both markers indicated bacteraemia (BDG <80 pg/ml and PCT ≥2 ng/ml), their NPV for candidaemia was similar to that of BDG used alone (95% vs. 93%). Discordant BDG and PCT results (i.e. one indicating candidaemia and the other bacteraemia) only slightly altered the pre-test probabilities of the two diseases. CONCLUSIONS: The combined use of PCT and BDG could be helpful in the diagnostic workflow for critically ill patients with suspected candidaemia.


Assuntos
Bacteriemia/mortalidade , Calcitonina/análise , Candidemia/mortalidade , beta-Glucanas/análise , Adulto , Idoso , Bacteriemia/diagnóstico , Biomarcadores/análise , Biomarcadores/sangue , Calcitonina/sangue , Candidemia/diagnóstico , Diagnóstico Diferencial , Feminino , Humanos , Unidades de Terapia Intensiva/organização & administração , Itália , Masculino , Pessoa de Meia-Idade , Proteoglicanas , beta-Glucanas/sangue
7.
Mycoses ; 60(12): 789-795, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28833726

RESUMO

Plasma 1,3-ß-D-glucan (BDG) is indicated as a tool for early diagnosis of invasive fungal diseases (IFD). However, data on its diagnostic value are scarce in children. Therefore, definition of BDG test performance in paediatrics is needed. BDG was evaluated in children admitted to "Istituto Giannina Gaslini," Genoa, Italy, who developed clinical conditions at risk for IFD. Results were analysed for sensitivity, specificity, predictive values, likelihood ratios, accuracy, informedness and probability of missing one case by a negative test. A total of 1577 BDG determinations were performed on 255 patients (49% males, median age 5.4 years). Overall 46 IFD were diagnosed, 72% proven/probable. The test performance was evaluated for 80 pg/mL, 120 pg/mL, 200 pg/mL, 350 pg/mL, 400 pg/mL cut offs. Sensitivity was always <0.80 and specificity > 0.90 only for cut offs ≥200 pg/mL. Negative predictive value was ≥0.90 for all the cut offs evaluated, while positive predictive value resulted barely 0.50 (8% IFD prevalence). Accuracy was never >0.90, and informedness was at best 0.50. The risk of missing one IFD by a negative result was < 10%. Analyses in haemato-oncological or newborn patients did not show major differences. Detection of serum BDG does not appear a valuable adjunctive diagnostic tool for IFD in paediatrics.


Assuntos
Técnicas e Procedimentos Diagnósticos , Infecções Fúngicas Invasivas/diagnóstico , beta-Glucanas/sangue , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Infecções Fúngicas Invasivas/sangue , Infecções Fúngicas Invasivas/microbiologia , Itália , Masculino , Curva ROC , Sensibilidade e Especificidade
9.
Clin Microbiol Infect ; 28(8): 1154.e1-1154.e3, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35283316

RESUMO

OBJECTIVES: Serum (1,3)-beta-d-glucan (BDG) assay is a non-culture-based test recommended for the diagnosis of invasive candidiasis owing to its faster results and higher sensitivity than blood cultures. Its performance might vary for different Candida species. The aim of this study was to determine in vitro levels of BDG in Candida auris culture supernatants and evaluate BDG levels in patients with C. auris candidemia sustained by these stains. METHODS: C. auris strains were collected from blood cultures of patients who had a concomitant (-24 to +72 hours) serum BDG test (Fungitell assay). Supernatants of broth media culture of C. auris strains and two Candida albicans (controls) strains were prepared and tested for BDG. RESULTS: Ten C auris strains were included. Supernatants of two C. albicans considered as controls had a mean BDG level of 1155 pg/mL (considered 100% reactivity). The median BDG level in supernatants of C. auris strains was 275 pg/mL (IQR 165-523 pg/mL), with a median reactivity of 24% (range 6%-72%). In vivo, the median BDG level was 129 pg/mL (IQR, 28-199 pg/mL). Sensitivity of BDG for C. auris candidemia was 60%. All patients received antifungal treatment with an echinocandin initiated a median of 2 days (IQR -8 to 0) before blood collection for BDG. DISCUSSION: Our C. auris strains released lower amounts of BDG when compared to C. albicans. Clinical implications include lower sensitivity of serum BDG for the diagnosis of C. auris candidemia with a consequent impact on management protocols in settings with high prevalence of this species.


Assuntos
Candidemia , Candidíase Invasiva , beta-Glucanas , Antifúngicos/farmacologia , Antifúngicos/uso terapêutico , Candida auris , Candidemia/diagnóstico , Candidemia/tratamento farmacológico , Candidíase Invasiva/diagnóstico , Candidíase Invasiva/tratamento farmacológico , Glucanos , Humanos , Sensibilidade e Especificidade
12.
Expert Rev Anti Infect Ther ; 13(1): 103-17, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25385534

RESUMO

Invasive fungal diseases carry a high mortality risk which can be reduced by early treatment. Diagnosing invasive fungal diseases is challenging, because invasive methods for obtaining histological samples are frequently not feasible in thrombocytopenic immunocompromised patients, while fungal cultures have low sensitivity and a long turn-around time. Non-cultural methods are fundamental for a rapid diagnosis of invasive fungal diseases and they include assays based on the detection of fungal antigens (galactomannan, Aspergillus-lateral flow device, [1,3]-ß-D-glucan, mannan), antibodies, such as anti-mannan, and molecular tests. With the exception of some molecular methods for rare fungi, the non-cultural assays are usually applied to the diagnosis of invasive aspergillosis, invasive candidiasis and pneumocystosis. The performance of a single test or a combination of tests will be discussed, with particular focus on choosing the most appropriate marker(s) for every specific patient population. Reasons for potential false-positive or false-negative results will be discussed.


Assuntos
Antígenos de Fungos/análise , Candidíase Invasiva/diagnóstico , Aspergilose Pulmonar Invasiva/diagnóstico , Galactose/análogos & derivados , Humanos , Mananas/análise , Técnicas Microbiológicas , Reação em Cadeia da Polimerase/métodos , beta-Glucanas/análise
13.
Indian J Pediatr ; 81(9): 856-60, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24014186

RESUMO

OBJECTIVE: To investigate the plasma levels of lopinavir by enzyme-linked immunosorbent assay (ELISA) in a cohort of patients who were vertically infected with human immunodeficiency virus 1 (HIV). METHODS: Plasma levels of lopinavir (Cmin) were determined by ELISA test in patients treated with lopinavir/ritonavir-based combined antiretroviral therapy who had achieved virological response after 4 wk of therapy. Reference lopinavir concentrations were Cmin 1-8 µg/mL. Correlation between lopinavir plasma concentration and continuous variables was evaluated by mean of Pearson correlation coefficient. Differences in lopinavir (LPV) concentration for binary categorical variables were assessed by Mann-Whitney test, while for variables with more than two categories Kruskal-Wallis test was used. RESULTS: Thirty-four patients were enrolled; median age was 133 mo (15-265). The median lopinavir dose tested was 383.5 mg/kg (IQR: 266.6-400 mg/kg), with a median plasma concentration of 8.8 µg/mL (IQR: 5-14 µg/mL). Lopinavir Cmin was <1 µg/mL in only one sample (2.9 %), while 14 samples had Cmin between 1 and 8 µg/mL (41.2 %) and 19 (55.9 %) > 8 µg/mL. No significant correlations were found between plasma concentrations of lopinavir and the continuous variables considered in the study. A negative but, not completely significant, correlation was found between plasma drug concentration and body mass index (r = -0.29; p = 0.09). CONCLUSIONS: The use of a simple and relatively cost-effective methodology might render therapeutic drug monitoring (TDM) appeal in the daily clinical practice.


Assuntos
Ensaio de Imunoadsorção Enzimática , Infecções por HIV/metabolismo , Infecções por HIV/transmissão , Inibidores da Protease de HIV/farmacocinética , Transmissão Vertical de Doenças Infecciosas , Lopinavir/farmacocinética , Adolescente , Criança , Pré-Escolar , Feminino , Infecções por HIV/sangue , Humanos , Lactente , Lopinavir/sangue , Masculino , Adulto Jovem
14.
J Infect ; 66(3): 218-38, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23178421

RESUMO

OBJECTIVES: To describe the pathogenesis, clinical presentation, cerebrospinal fluid findings and outcome of Aspergillus meningitis, meningoencephalitis and arachnoiditis. METHODS: A case of Aspergillus meningitis is described. A comprehensive review of the English-language literature was conducted to identify all reported cases of Aspergillus meningitis described between January 1973 and December 2011. RESULTS: Ninety-three cases (including the one described herein) of Aspergillus meningitis were identified. Fifty-two (55.9%) were in individuals without any predisposing factor or known causes of immunosuppression. Acute and chronic meningitis was diagnosed in 65.6% of patients and meningoencephalitis in 24.7% of them with the remaining presenting with spinal arachnoiditis and ventriculitis. Cerebrospinal fluid cultures for Aspergillus spp. were positive in about 31% of cases and the galactomannan antigen test in 87%. Diagnosis during life was achieved in 52 patients (55.9%) with a case fatality rate of 50%. The overall case fatality rate was 72.1%. CONCLUSIONS: Aspergillus meningitis may occur in both immunocompetent and immunocompromised patients and run an acute or chronic course. The findings of this systematic review extend the information on this life-threatening infection and could assist physicians in achieving an improved outcome.


Assuntos
Aspergilose/patologia , Aspergillus flavus/isolamento & purificação , Meningite Fúngica/patologia , Adulto , Aspergilose/microbiologia , Sistema Nervoso Central/microbiologia , Sistema Nervoso Central/patologia , Líquido Cefalorraquidiano/microbiologia , Feminino , Humanos , Hospedeiro Imunocomprometido , Masculino , Meningite Fúngica/microbiologia
15.
Clin Vaccine Immunol ; 19(4): 626-7, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22357650

RESUMO

Fungal peritonitis is an unusual but severe complication of continuous peritoneal dialysis. The role of 1,3-ß-D-glucan is unknown in early diagnosis and in treatment monitoring of peritoneal candidiasis. This case report shows the utility of 1,3-ß-D-glucan monitoring in management of Candida peritonitis in a child undergoing continuous peritoneal dialysis.


Assuntos
Líquido Ascítico/química , Candidíase/diagnóstico , Candidíase/tratamento farmacológico , Monitoramento de Medicamentos/métodos , Diálise Peritoneal/efeitos adversos , Peritonite/tratamento farmacológico , beta-Glucanas/análise , Candidíase/microbiologia , Pré-Escolar , Humanos , Masculino , Peritonite/microbiologia , Proteoglicanas
16.
Diagn Microbiol Infect Dis ; 72(4): 367-9, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22280997

RESUMO

Galactomannan (GM) is used to diagnose aspergillosis. We present a case of a hematopoietic stem cell transplantation recipient with fusariosis who received early antifungal treatment based on GM positivity. Additionally, 3 Fusarium isolates tested positive for GM. Fusarium is another mold containing GM. GM might be useful for diagnosing fusariosis in high-risk patients.


Assuntos
Antifúngicos/uso terapêutico , Fusariose/diagnóstico , Fusarium/isolamento & purificação , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Mananas/sangue , Diagnóstico Precoce , Evolução Fatal , Feminino , Fusariose/tratamento farmacológico , Fusariose/microbiologia , Fusarium/classificação , Fusarium/efeitos dos fármacos , Fusarium/genética , Galactose/análogos & derivados , Humanos , Pessoa de Meia-Idade , beta-Glucanas/sangue
17.
Clin Vaccine Immunol ; 18(12): 2113-7, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21994353

RESUMO

Microbiological diagnosis of nosocomial candidemia is negatively affected by suboptimal culture yield. Alternative methods are not fully reliable as an aid in candidemia diagnosis. Recently, the detection of (1,3)-ß-D-glucan (BG) has been shown to be very promising in this setting. We carried out a prospective study on the clinical usefulness of BG detection in early diagnosis of candidemia. BG detection was performed in patients with fever unresponsive to antibacterial agents and risk factors for candidemia. BG detection was done with the Fungitell test. A total of 152 patients were included in the study; 53 were proven to have candidemia, while in 52 patients candidemia was excluded on microbiological and clinical bases. The remaining 47 patients were considered to have possible candidemia. In summary, 41 of 53 candidemia patients (77.3%), 9 of 52 patients without candidemia (17.3%), and 38 of 47 patients with possible candidemia (80.8%) were positive in the BG assay. With these results, the sensitivity and the specificity of the assay were 77% and 83%, respectively. BG levels of >160 pg/ml were highly predictive of candidemia. In 36 of 41 patients with candidemia and positive BG testing, the BG assay was performed within 48 h from when the first Candida-positive blood sample for culture was drawn, thus allowing a possible earlier start of antifungal therapy. Based on these results, the BG assay may be used as an aid in the diagnosis of nosocomial candidemia. The timing of assay performance is critical for collecting clinically useful information. However, the test results should be associated with clinical data.


Assuntos
Antígenos de Fungos/sangue , Candidemia/diagnóstico , Técnicas de Laboratório Clínico/métodos , beta-Glucanas/sangue , Infecção Hospitalar/diagnóstico , Diagnóstico Precoce , Humanos , Imunoensaio/métodos , Estudos Prospectivos , Sensibilidade e Especificidade
18.
Clin Vaccine Immunol ; 17(5): 882-3, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20335432

RESUMO

The plasmatic levels of 1,3-beta-d-glucan (BDG) were >523 pg/ml in 4 children, 2 low-birth-weight neonates and 2 stem cell transplant recipients, with the following invasive fungal diseases (IFD) proven apart from this BDG test: 3 cases of Candida parapsilosis candidemias and 1 case of disseminated aspergillosis. The BDG test may be useful for identification of IFD in pediatrics.


Assuntos
Aspergilose/patologia , Candidíase/patologia , Fungemia/patologia , Hospedeiro Imunocomprometido , beta-Glucanas/sangue , Aspergilose/microbiologia , Aspergillus/isolamento & purificação , Candida/isolamento & purificação , Candidíase/microbiologia , Criança , Feminino , Humanos , Recém-Nascido , Masculino , Proteoglicanas
19.
Clin Vaccine Immunol ; 16(10): 1524-6, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19692624

RESUMO

(1,3)-beta-d-Glucan (BG) is a component of the Pneumocystis jiroveci cell wall. Thirty-one immunocompromised patients with pneumonia (16 with presumptive pneumocystis pneumonia [PCP] and 15 with non-PCP) were evaluated for serum BG levels. Serum from all 16 presumptive PCP patients and from 2/15 patients with non-PCP was positive for BG. Results indicate that BG is a reliable marker for diagnosing PCP.


Assuntos
Pneumocystis carinii , Pneumonia por Pneumocystis/diagnóstico , beta-Glucanas/sangue , Biomarcadores/sangue , Estudos de Casos e Controles , Parede Celular/química , Humanos , Hospedeiro Imunocomprometido , Pneumocystis carinii/imunologia , Pneumocystis carinii/isolamento & purificação , Pneumonia por Pneumocystis/imunologia , Pneumonia por Pneumocystis/microbiologia , Proteoglicanas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA